Filing Details
- Accession Number:
- 0001209191-23-003857
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-01-18 19:05:54
- Reporting Period:
- 2023-01-13
- Accepted Time:
- 2023-01-18 19:05:54
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1787400 | Nkarta Inc. | NKTX | Pharmaceutical Preparations (2834) | 474515206 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1816549 | James Trager | C/O Nkarta, Inc. 6000 Shoreline Court, Suite 102 South San Francisco CA 94080 | Chief Scientific Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2023-01-13 | 37,500 | $0.00 | 99,672 | No | 4 | A | Direct | |
Common Stock | Disposition | 2023-01-17 | 1,115 | $5.49 | 98,557 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (right to buy) | Acquisiton | 2023-01-13 | 75,000 | $0.00 | 75,000 | $5.57 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
75,000 | 2033-01-12 | No | 4 | A | Direct |
Footnotes
- Represents Restricted Stock Units ("RSUs") which vest in four equal annual installments beginning on January 14, 2024. Each RSU represents a contingent right to receive one share of Common Stock of the Issuer.
- Represents shares sold to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a discretionary transaction by the Reporting Person.
- This transaction was executed in multiple trades at prices ranging from $5.49 to $5.56. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
- This option is scheduled to vest and become exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 14, 2023.